8
views
0
recommends
+1 Recommend
2 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Acromegaly remission, SIADH and pituitary function recovery after macroadenoma apoplexy

      research-article
      1 , 2 , 3 , 1
      Endocrinology, Diabetes & Metabolism Case Reports
      Bioscientifica Ltd
      Adult, Male, White, Spain, Pituitary, Pituitary, Thyroxine (T4), TSH, FSH, LH, Testosterone, GH, Antidiuretic Hormone, Pituitary apoplexy, Pituitary adenoma, Acromegaly, SIADH, Hyponatraemia, Pituitary haemorrhage, Hypopituitarism, Headache, Hypopituitarism, Hyponatraemia, Concentration difficulties, Fatigue, Feet - increased size, Gynaecomastia, CT scan, MRI, IGF1, Sodium, Dexamethasone suppression, FT4, TSH, Cortisol, FSH, LH, GH, Testosterone, Serum osmolality, ACTH stimulation, Fluid repletion, Fluid restriction, Saline, Hydrocortisone, Glucocorticoids, Dexamethasone, Podiatry, Unique/unexpected symptoms or presentations of a disease, July, 2019

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Pituitary apoplexy is a rare but potentially life-threatening clinical syndrome characterised by ischaemic infarction or haemorrhage into a pituitary tumour that can lead to spontaneous remission of hormonal hypersecretion. We report the case of a 50-year-old man who attended the emergency department for sudden onset of headache. A computed tomography (CT) scan at admission revealed pituitary haemorrhage and the blood test confirmed the clinical suspicion of acromegaly and an associated hypopituitarism. The T1-weighted magnetic resonance imaging (MRI) showed the classic pituitary ring sign on the right side of the pituitary. Following admission, he developed acute-onset hyponatraemia that required hypertonic saline administration, improving progressively. Surprisingly, during the follow-up, IGF1 levels became normal and he progressively recovered pituitary function.

          Learning points:
          • Patients with pituitary apoplexy may have spontaneous remission of hormonal hypersecretion. If it is not an emergency, we should delay a decision to undertake surgery following apoplexy and re-evaluate hormone secretion.

          • Hyponatraemia is an acute sign of hypocortisolism in pituitary apoplexy. However, SIADH although uncommon, could appear later as a consequence of direct hypothalamic insult and requires active and individualised treatment. For this reason, closely monitoring sodium at the beginning of the episode and throughout the first week is advisable to guard against SIADH.

          • Despite being less frequent, if pituitary apoplexy is limited to the tumour, the patient can recover pituitary function previously damaged by the undiagnosed macroadenoma.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Pituitary Apoplexy.

          Pituitary apoplexy, a rare clinical syndrome secondary to abrupt hemorrhage or infarction, complicates 2%-12% of pituitary adenomas, especially nonfunctioning tumors. Headache of sudden and severe onset is the main symptom, sometimes associated with visual disturbances or ocular palsy. Signs of meningeal irritation or altered consciousness may complicate the diagnosis. Precipitating factors (increase in intracranial pressure, arterial hypertension, major surgery, anticoagulant therapy or dynamic testing, etc) may be identified. Corticotropic deficiency with adrenal insufficiency may be life threatening if left untreated. Computed tomography or magnetic resonance imaging confirms the diagnosis by revealing a pituitary tumor with hemorrhagic and/or necrotic components. Formerly considered a neurosurgical emergency, pituitary apoplexy always used to be treated surgically. Nowadays, conservative management is increasingly used in selected patients (those without important visual acuity or field defects and with normal consciousness), because successive publications give converging evidence that a wait-and-see approach may also provide excellent outcomes in terms of oculomotor palsy, pituitary function and subsequent tumor growth. However, it must be kept in mind that studies comparing surgical approach and conservative management were retrospective and not controlled.
            • Record: found
            • Abstract: found
            • Article: not found

            The syndrome of inappropriate antidiuresis (SIAD).

            Hyponatraemia is the commonest electrolyte disturbance encountered in clinical practice and the syndrome of inappropriate antidiuresis (SIADH) is the most frequent underlying disorder. There is a well-recognized relationship between hyponatraemia and increased morbidity and mortality, though it is unknown whether SIADH confers the same mortality as other causes of hyponatraemia. SIADH is the biochemical manifestation of a wide variety of diseases, and the pathophysiology of SIADH is sometimes multiple. There have been significant advances in the treatment of SIADH over the last 10 years, in particular since the introduction of the vasopressin-2 receptor antagonists, which provide a potent, disease-specific tool which targets the underlying pathophysiology of SIADH. The mechanisms and the evidence base recommendations of the available therapies for SIADH are discussed in this article. The various guidelines and recommendations for treatment of hyponatraemia all emphasise that fluid restriction is first line therapy for SIADH, but we feel that it is ineffective or unfeasible in many patients. A number of key points relevant to the use of fluid restriction are presented in the manuscript. The clinical efficacy of tolvaptan in SIADH supported by good quality randomized, placebo controlled, clinical trials. However, the cost of the therapy and the need for long term safety data may limit its widespread use. Finally, new recommendations for the management of acute hyponatraemia, with a focus on the use of bolus therapy with 3% hypertonic sodium chloride is described.
              • Record: found
              • Abstract: found
              • Article: not found

              Management of endocrine disease: pituitary tumour apoplexy.

              Pituitary tumour apoplexy (PA) is a rare clinical syndrome that occurs as a result of acute haemorrhage and/or infarction within a frequently undiagnosed pituitary tumour. The sudden enlargement of the pituitary mass undergoing PA is responsible for a wide range of acute symptoms/signs (severe headache, visual loss, diplopia, hypopituitarism, impaired consciousness) which, together with the radiological evidence of a pituitary lesion, establish the diagnosis. The optimal care of PA requires involvement of a multidisciplinary team including endocrinologist, neurosurgeon, neuroophthalmologist and the management strategy that depends on the clinical manifestations, as well as the presence of co-morbidities. Prompt surgical decompression is initially indicated in cases with severe or progressive impairment of the visual acuity or the visual fields or with altered mental state and leads to visual and neurological recovery in most of the patients. The patients with mild, stable clinical picture (including those with isolated ocular palsies) can be managed conservatively (support of fluid and electrolyte balance and stress doses of steroids in most cases) with favourable visual and neurological outcome. Frequent reassessment is mandatory because the clinical course can be unpredictable; if progression of symptoms occurs, later elective surgery is indicated and is beneficial, especially in terms of visual outcome. The endocrinological outcome is less favourable, irrespective of the treatment option, with many patients remaining on long-term replacement therapy. Despite the above guidelines, clear proof of optimal outcomes in the form of randomised controlled trials is lacking. Regrowth of the pituitary tumour years after a PA episode is possible and patients require long-term surveillance.

                Author and article information

                Journal
                Endocrinol Diabetes Metab Case Rep
                Endocrinol Diabetes Metab Case Rep
                EDM
                Endocrinology, Diabetes & Metabolism Case Reports
                Bioscientifica Ltd (Bristol )
                2052-0573
                15 July 2019
                2019
                : 2019
                : 19-0057
                Affiliations
                [1 ]Endocrinology , Vall d’Hebron Hospital, Barcelona, Spain
                [2 ]Radiology , Vall d’Hebron Hospital, Barcelona, Spain
                [3 ]Neurosurgery , Vall d’Hebron Hospital, Barcelona, Spain
                Author notes
                Correspondence should be addressed to B Biagetti; Email: bbiagetti@ 123456vhebron.net
                Article
                EDM190057
                10.1530/EDM-19-0057
                8115412
                31310082
                19225b3f-4187-4447-9518-3c8500ec2e10
                © 2019 The authors

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License..

                History
                : 11 June 2019
                : 26 June 2019
                Categories
                Adult
                Male
                White
                Spain
                Pituitary
                Pituitary
                Thyroxine (T4)
                TSH
                FSH
                LH
                Testosterone
                GH
                Antidiuretic Hormone
                Pituitary apoplexy
                Pituitary adenoma
                Acromegaly
                SIADH
                Hyponatraemia
                Pituitary haemorrhage
                Hypopituitarism
                Headache
                Hypopituitarism
                Hyponatraemia
                Concentration difficulties
                Fatigue
                Feet - increased size
                Gynaecomastia
                CT scan
                MRI
                IGF1
                Sodium
                Dexamethasone suppression
                FT4
                TSH
                Cortisol
                FSH
                LH
                GH
                Testosterone
                Serum osmolality
                ACTH stimulation
                Fluid repletion
                Fluid restriction
                Saline
                Hydrocortisone
                Glucocorticoids
                Dexamethasone
                Podiatry
                Unique/Unexpected Symptoms or Presentations of a Disease
                Unique/Unexpected Symptoms or Presentations of a Disease

                adult,male,white,spain,pituitary,thyroxine (t4),tsh,fsh,lh,testosterone,gh,antidiuretic hormone,pituitary apoplexy,pituitary adenoma,acromegaly,siadh,hyponatraemia,pituitary haemorrhage,hypopituitarism,headache,concentration difficulties,fatigue,feet - increased size,gynaecomastia,ct scan,mri,igf1,sodium,dexamethasone suppression,ft4,cortisol,serum osmolality,acth stimulation,fluid repletion,fluid restriction,saline,hydrocortisone,glucocorticoids,dexamethasone,podiatry,unique/unexpected symptoms or presentations of a disease,july,2019

                Comments

                Comment on this article

                Related Documents Log